New drug duo takes on Hard-to-Treat kidney cancer
NCT ID NCT06234605
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new oral drug called HC-7366 combined with the approved drug belzutifan in about 80 adults with advanced kidney cancer that cannot be surgically removed. The main goal is to find the safest dose and check for any serious side effects. Researchers will also watch for signs that the combination can shrink or control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HC-7366 (a drug that activates a protein called GCN2) combined with belzutifan (a drug that blocks HIF-2α)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with advanced kidney cancer that has not responded to other therapies.
What could go wrong
This is an early Phase 1b trial with only 80 participants, so the main goal is safety and dosing—not proof of effectiveness. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Email: •••••@•••••
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact Email: •••••@•••••
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact Email: •••••@•••••
-
HealthPartners Cancer Research Center
RECRUITINGSaint Paul, Minnesota, 55101, United States
Contact Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
-
Providence Cancer Institute
RECRUITINGPortland, Oregon, 97213, United States
Contact Email: •••••@•••••
-
Rocky Mountain Cancer Centers, LLP
RECRUITINGLone Tree, Colorado, 80124, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Swedish Medical Center
RECRUITINGSeattle, Washington, 98104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Texas Oncology
RECRUITINGDallas, Texas, 75246, United States
Contact Email: •••••@•••••
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact Email: •••••@•••••
-
University Medical Center & Texas Tech Health Science Center
RECRUITINGLubbock, Texas, 79430, United States
Contact Email: •••••@•••••
-
University of Arizona Cancer Center
RECRUITINGTucson, Arizona, 85719, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
Contact Email: •••••@•••••
-
University of Colorado Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Contact Email: •••••@•••••
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
-
University of Wisconsin - Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
-
Yale - New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Email: •••••@•••••